PH12021553284A1 - Prostate specific membrane antigen (psma) ligands and uses thereof - Google Patents

Prostate specific membrane antigen (psma) ligands and uses thereof

Info

Publication number
PH12021553284A1
PH12021553284A1 PH1/2021/553284A PH12021553284A PH12021553284A1 PH 12021553284 A1 PH12021553284 A1 PH 12021553284A1 PH 12021553284 A PH12021553284 A PH 12021553284A PH 12021553284 A1 PH12021553284 A1 PH 12021553284A1
Authority
PH
Philippines
Prior art keywords
psma
ligands
specific membrane
membrane antigen
prostate specific
Prior art date
Application number
PH1/2021/553284A
Other languages
English (en)
Inventor
Daniela Chicco
Lorenza Fugazza
Maurizio F Mariani
Martin Gilbert Pomper
Sangeeta Ray
Original Assignee
Advanced Accelerator Applications Italy Srl
Univ Johns Hopkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Accelerator Applications Italy Srl, Univ Johns Hopkins filed Critical Advanced Accelerator Applications Italy Srl
Publication of PH12021553284A1 publication Critical patent/PH12021553284A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PH1/2021/553284A 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof PH12021553284A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19184015 2019-07-02
PCT/EP2020/068386 WO2021001360A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Publications (1)

Publication Number Publication Date
PH12021553284A1 true PH12021553284A1 (en) 2022-08-01

Family

ID=67145647

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/553284A PH12021553284A1 (en) 2019-07-02 2020-06-30 Prostate specific membrane antigen (psma) ligands and uses thereof

Country Status (16)

Country Link
US (1) US20230226227A1 (enExample)
EP (1) EP3993837A1 (enExample)
JP (2) JP7805170B2 (enExample)
KR (1) KR20220044496A (enExample)
CN (3) CN120441497A (enExample)
AR (1) AR119331A1 (enExample)
AU (3) AU2020299974A1 (enExample)
BR (1) BR112021026812A2 (enExample)
CA (1) CA3144557A1 (enExample)
CL (1) CL2021003525A1 (enExample)
CO (1) CO2021017708A2 (enExample)
IL (1) IL289039A (enExample)
MX (1) MX2022000136A (enExample)
PH (1) PH12021553284A1 (enExample)
TW (1) TW202114742A (enExample)
WO (1) WO2021001360A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219719A1 (en) * 2020-04-29 2021-11-04 Advanced Accelerator Applications (Italy) Srl Methods for radiolabelling psma binding ligands and their kits
CN121604981A (zh) 2023-07-21 2026-03-03 诺华公司 靶向psma的放射性配体治疗方案
WO2025125469A1 (en) 2023-12-13 2025-06-19 Swiss Rockets Ag Combination therapy using psma-targeted radiopharmaceuticals and an inhibitor of pi3k, akt, and/or mtor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001271026A1 (en) 2000-07-11 2002-01-21 Bml, Inc. Remedies for bone diseases
HUE045028T2 (hu) * 2011-08-05 2019-12-30 Molecular Insight Pharm Inc Radiojelzett prosztataspecifikus membrán antigén inhibitorok
GEP20237479B (en) * 2013-10-18 2023-03-27 Deutsches Krebsforsch Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR20250057132A (ko) 2016-03-22 2025-04-28 더 존스 홉킨스 유니버시티 전립선 암의 내부방사선요법을 위한 전립선-특이적 막 항원 표적화된 고-친화성 제제
US11478558B2 (en) * 2017-05-30 2022-10-25 The Johns Hopkins University Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
IL276528B2 (en) * 2018-02-06 2024-11-01 Univ Johns Hopkins PSMA Targeted Radiohalogenated Urea-Polyaminocarboxylates For Cancer Radiotherapy
WO2020028323A1 (en) * 2018-07-30 2020-02-06 The Johns Hopkins Universtiy Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy

Also Published As

Publication number Publication date
JP2025165975A (ja) 2025-11-05
CO2021017708A2 (es) 2022-05-20
BR112021026812A2 (pt) 2022-02-22
CN120441497A (zh) 2025-08-08
WO2021001360A1 (en) 2021-01-07
EP3993837A1 (en) 2022-05-11
JP2022538478A (ja) 2022-09-02
MX2022000136A (es) 2022-04-27
AU2020299974A1 (en) 2022-01-27
AR119331A1 (es) 2021-12-09
TW202114742A (zh) 2021-04-16
US20230226227A1 (en) 2023-07-20
AU2024200850A1 (en) 2024-02-29
CN114341118A (zh) 2022-04-12
AU2024200850B2 (en) 2025-09-04
IL289039A (en) 2022-02-01
CN120441498A (zh) 2025-08-08
KR20220044496A (ko) 2022-04-08
AU2025271182A1 (en) 2025-12-18
CA3144557A1 (en) 2021-01-07
JP7805170B2 (ja) 2026-01-23
CL2021003525A1 (es) 2022-10-21

Similar Documents

Publication Publication Date Title
MX2024015039A (es) Composiciones anti-cd24 y usos de las mismas
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12020550898A1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
CR20210556A (es) Quelantes macrocíclicos y métodos de uso de estos
PH12021553284A1 (en) Prostate specific membrane antigen (psma) ligands and uses thereof
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
MX2021000392A (es) Anticuerpos anti-mesotelina.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
MX2024007724A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado
MX2021003187A (es) Inhibición de la peptidasa específica de ubiquitina 9x.
AR110056A2 (es) Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos
GEP20217330B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
CL2017001580A1 (es) Anticuerpo o fragmento de anticuerpo contra cd38 anticuerpo humanizado, conjugado del anticuerpo con un compuesto citotoxico composición farmacéutica con dichos anticuerpos uso de los anticuerpos para tratar cáncer o enfermedad autoinmune método para diagnosticar cáncer polinucleotido vector y célula huésped.
MX2020002241A (es) Anticuerpos anti-tm4sf y métodos de uso de los mismos.
WO2019234241A8 (en) ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT
CR20220156A (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
PH12022550894A1 (en) Ri-labeled humanized antibody
MX2021000213A (es) Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acidico.
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.
PE20200866A1 (es) Composiciones que contienen conjugados de analogos cannabinoides y metodos de uso
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
MX386402B (es) Tratamiento con trastuzumab vc-seco-duba de pacientes de cáncer refractarios a trastuzumab emtansina.
ECSP045408A (es) Composición farmacéutica que comprende arsenito para el tratamiento de malignidad